(12) United States Patent (10) Patent No.: US 8,486,925 B2 Malladi Et Al

Total Page:16

File Type:pdf, Size:1020Kb

(12) United States Patent (10) Patent No.: US 8,486,925 B2 Malladi Et Al USOO8486925B2 (12) United States Patent (10) Patent No.: US 8,486,925 B2 Malladi et al. (45) Date of Patent: *Jul. 16, 2013 (54) TESTOSTERONE GEL AND METHOD OF 4,496.455 A 1/1985 Linder et al. USE 4,496.556 A 1/1985 Orentreich 4,557,934 A 12/1985 Cooper 4,563,473 A 1/1986 Hofman et al. (75) Inventors: Ramana Malladi, Marietta, GA (US); 4,615,697 A 10, 1986 Robinson Jodi Miller, Marietta, GA (US) 4,631,188 A 12/1986 Stoy et al. 4,663,157 A 5, 1987 Brock (73) Assignees: Unimed Pharmaceuticals, LLC. Abbott 4,683,242 A 7, 1987 Poser 4,690,775 A 9, 1987 Schott et al. Park, IL (US); Laboratoires Besins 4,695.465 A 9/1987 Kigasawa et al. International, SAS, Paris (FR) 4,699,779 A 10, 1987 Palinczar 4,704,282 A 1 1/1987 Campbell et al. (*) Notice: Subject to any disclaimer, the term of this 4,725,439 A 2/1988 Campbell et al. patent is extended or adjusted under 35 4,745,160 A 5/1988 Churchill et al. U.S.C. 154(b) by 0 days. 4,767,627 A 8, 1988 Caldwell et al. 4,780,320 A 10, 1988 Baker This patent is Subject to a terminal dis 4,788,062 A 11/1988 Gale et al. claimer. 4,791,099 A 12/1988 Aroonsakul 4,820,724 A 4, 1989 Nimni 4,855.305 A 8, 1989 Cohen (21) Appl. No.: 13/253,867 4,861,764 A 8, 1989 Samour et al. 4,863,911 A 9, 1989 Anderson et al. (22) Filed: Oct. 5, 2011 4,863,970 A 9, 1989 Patel et al. 4,867,982 A 9/1989 Campbell et al. (65) Prior Publication Data 4,906, 169 A 3, 1990 Chien et al. 4.919,937 A 4, 1990 Mauvais-Jarvis et al. US 2012/0028948 A1 Feb. 2, 2012 4,920,203 A 4/1990 Tang et al. 4.946,870 A 8, 1990 Partain et al. 4.954,487 A 9/1990 Cooper et al. Related U.S. Application Data 4,981,696 A 1/1991 Loomis et al. 4,994.265 A 2, 1991 White (62) Division of application No. 1 1/549,083, filed on Oct. 12, 2006, now abandoned. (Continued) (60) Provisional application No. 60/725,276, filed on Oct. FOREIGN PATENT DOCUMENTS AU 4998.490 9, 1990 12, 2005. AU 914 1391 6, 1992 (51) Int. Cl. (Continued) A6 IK3I/56 (2006.01) A6 IK3I/568 (2006.01) OTHER PUBLICATIONS C07 L/00 (2006.01) CD7C 49/00 (2006.01) U.S. Appl. No. 13/275,254, filed Oct. 2011, Dudley et al.* (52) U.S. Cl. U.S. Appl. No. 13/180,316, filed Jul. 2011, Malladi.* USPC ............ 514/177, 514/178; 552/638; 568/369 U.S. Appl. No. 13/165,545, filed Jun. 2011, Dudley et al.* (58) Field of Classification Search U.S. Appl. No. 13/071,264, filed Mar. 2011, Dudley et al.* USPC .................... 514/177, 178; 552/638; 568/369 2232508, Mar. 16, 1999, Unimed Pharmaceuticals, LLC. See application file for complete search history. U.S. Appl. No. 09/703,753 (abandoned), filed Nov. 1, 2000. U.S. Appl. No. 09/892,981 (abandoned), filed Jun. 27, 2001. (56) References Cited U.S. Appl. No. 10/033,101 (abandoned), filed Oct. 19, 2001. U.S. Appl. No. 10/046,454 (abandoned), filed Oct. 19, 2001. U.S. PATENT DOCUMENTS U.S. Appl. No. 10/098,232 (abandoned), filed Mar. 15, 2002. 2,155,658 A 4, 1939 Herrman et al. U.S. Appl. No. 10/099,725 (abandoned), filed Mar. 15, 2002. 3,068,188 A 12/1962 Beste et al. 3,121,042 A 2f1964 Ercoli (Continued) 3,164,520 A 1, 1965 Huber 3,218,283 A 11, 1965 Miller 3,887,699 A 6, 1975 Yoles 3,888,995 A 6, 1975 Katz et al. Primary Examiner — Kara R McMillian 3,913,789 A 10, 1975 Miller (74) Attorney, Agent, or Firm — Lisa V. Mueller; Michael 3,939,111 A 2/1976 Schollenberger et al. Best & Friedrich LLP 3,989,816 A 11/1976 Rajadhyaksha 4,009,254 A 2, 1977 Renold 4,078,060 A 3, 1978 Benson 4,083,973 A 4, 1978 Van der Vies (57) ABSTRACT 4,161,948 A 7, 1979 Bichon 4,197,316 A 4, 1980 Yu et al. The present invention relates to an improved transdermal 4,299,826 A 11, 1981 Luedders hydroalcoholic testosterone gel formulation that provides, 4,346,709 A 8, 1982 Schimitt among other things, a desirable pharmacokinetic hormone 4.424,363 A 1, 1984 Plath et al. 4,440,777 A 4, 1984 Zupan profile, and methods of use. 4,442,094. A 4, 1984 Atkinson et al. 4,447.562 A 5, 1984 Ivani 4.478,822 A 10, 1984 Haslam et al. 7 Claims, 6 Drawing Sheets US 8,486.925 B2 Page 2 U.S. PATENT DOCUMENTS 5,849,729 12, 1998 Zoumas et al. 5,855,905 1/1999 Oettel et al. 5,013,553 5, 1991 Southard et al. 5,855,920 1/1999 Chein 5,023,252 6, 1991 HSeih 5,859,006 1/1999 Daugan 5,026,692 6, 1991 Kuno et al. 5,863,560 1/1999 Osborne 5,036,100 7, 1991 Deboeck et al. 5,874,074 2, 1999 Smith 5,053,227 10, 1991 Chiang et al. RE36,138 3, 1999 Suzuki et al. 5,059,603 10, 1991 Rubin 5,877,216 3, 1999 Place et al. 5,071,657 12, 1991 Oloff et al. 5,880,117 3, 1999 Arnold 5,073,545 12, 1991 Arima et al. 5,881,926 3, 1999 Ross 5,116,828 5, 1992 Miura et al. 5,882,676 3, 1999 Lee et al. 5,122,519 6, 1992 Ritter 5,891.462 4, 1999 Carrara 5,152.997 10, 1992 Ebert et al. 5,894,019 4, 1999 Hesse et al. 5,200, 190 4, 1993 AZuma et al. 5,902,603 5, 1999 Chen et al. 5,208,013 5, 1993 Klein 5,906,830 5, 1999 Farinas et al. 5,223.261 6, 1993 Nelson et al. 5,908,619 6, 1999 Scholz 5,231,087 7, 1993 Thornfeldt 5,908.638 6, 1999 Huber et al. 5,231.382 7, 1993 Tanaka 5,926,953 7, 1999 Behar 5,232,703 8, 1993 Blank 5,932,227 8, 1999 Higo et al. 5,238,933 8, 1993 Catz et al. 5,935,949 8, 1999 White 5,238,944 8, 1993 Wicket al. 5,942,545 8, 1999 Samour et al. 5,256,652 10, 1993 El-Rashidy 5,952,000 9, 1999 Venkateshwaran et al. 5,324,521 6, 1994 Gertner et al. 5,955.455 9, 1999 Labrie 5,326,566 T. 1994 Parab 5,962,021 10, 1999 Hughes, Jr. et al. 5,326,790 T. 1994 Thornfeldt 5,968,919 10, 1999 Samour et al. 5,332,577 T. 1994 Gertner et al. 5,972,377 10, 1999 Jona et al. 5,340,584 8, 1994 Spicer et al. 5,981,542 11, 1999 Bigg et al. 5,340,585 8, 1994 Pike et al. 6,007,837 12, 1999 Enscore et al. 5,340,586 8, 1994 Pike et al. 6,010,716 1, 2000 Saunal et al. 5,346,901 9, 1994 Bell et al. 6,019,988 2, 2000 Parab et al. 5,362.497 11, 1994 Yamada et al. 6,019,997 2, 2000 Scholz et al. 5,362,886 11, 1994 Berglund 6,024,974 2, 2000 Li 5,413,794 5, 1995 Suzuki et al. 6,036,977 3, 2000 Drizen et al. 5,436,634 7, 1995 Kanazawa 6,037,346 3, 2000 Doherty, Jr. et al. 5,446,025 8, 1995 Lu 6,046,244 4, 2000 Buyuktimkin et al. 5,446,070 8, 1995 Mantelle 6,051,555 4, 2000 Hadley 5,460,820 10, 1995 Ebert et al. 6,071,531 6, 2000 Jona et al. 5,482,970 1, 1996 Kim et al. 6,075,028 6, 2000 Graham 5.487,898 1, 1996 Lu et al. 6,077,841 6, 2000 Sui et al. 5,550, 107 8, 1996 Labrie 6,087,362 T/2000 Ei-Rashidy 5,589.498 12, 1996 Mohr 6,087,368 T/2000 Macor et al. 5,607,691 3, 1997 Hale et al. 6,103,765 8, 2000 Neal 5,610,150 3, 1997 Labrie 6,117,446 9, 2000 Place 5,629,019 5, 1997 Lee et al. 6,124,461 9, 2000 Shoemaker 5,629,021 5, 1997 Wright 6,127,363 10, 2000 Doherty et al. 5,639,743 6, 1997 Kaswan et al. 6,132,760 10, 2000 Hedenstrom et al. 5,641,504 6, 1997 Lee et al. 6,133,320 10, 2000 Yallampalli et al. 5,643,899 7, 1997 Elias et al. 6,139,873 10, 2000 Hughes, Jr. et al. 5,648,350 7, 1997 DeLignieres 6,143,746 11, 2000 Daugan et al. 5,651,973 7, 1997 Moo-Young et al. 6,146,662 11, 2000 Jao et al. 5,654,337 8, 1997 Roentsch et al. 6,156,753 12, 2000 Doherty et al. 5,656,286 8, 1997 Miranda et al. 6,165,491 12, 2000 Grasset et al. 5,662.925 9, 1997 Ebert et al.
Recommended publications
  • News Deserts and Ghost Newspapers: Will Local News Survive?
    NEWS DESERTS AND GHOST NEWSPAPERS: WILL LOCAL NEWS SURVIVE? PENELOPE MUSE ABERNATHY Knight Chair in Journalism and Digital Media Economics Will Local News Survive? | 1 NEWS DESERTS AND GHOST NEWSPAPERS: WILL LOCAL NEWS SURVIVE? By Penelope Muse Abernathy Knight Chair in Journalism and Digital Media Economics The Center for Innovation and Sustainability in Local Media School of Media and Journalism University of North Carolina at Chapel Hill 2 | Will Local News Survive? Published by the Center for Innovation and Sustainability in Local Media with funding from the John S. and James L. Knight Foundation and the University of North Carolina at Chapel Hill Office of the Provost. Distributed by the University of North Carolina Press 11 South Boundary Street Chapel Hill, NC 27514-3808 uncpress.org Will Local News Survive? | 3 TABLE OF CONTENTS Preface 5 The News Landscape in 2020: Transformed and Diminished 7 Vanishing Newspapers 11 Vanishing Readers and Journalists 21 The New Media Giants 31 Entrepreneurial Stalwarts and Start-Ups 40 The News Landscape of the Future: Transformed...and Renewed? 55 Journalistic Mission: The Challenges and Opportunities for Ethnic Media 58 Emblems of Change in a Southern City 63 Business Model: A Bigger Role for Public Broadcasting 67 Technological Capabilities: The Algorithm as Editor 72 Policies and Regulations: The State of Play 77 The Path Forward: Reinventing Local News 90 Rate Your Local News 93 Citations 95 Methodology 114 Additional Resources 120 Contributors 121 4 | Will Local News Survive? PREFACE he paradox of the coronavirus pandemic and the ensuing economic shutdown is that it has exposed the deep Tfissures that have stealthily undermined the health of local journalism in recent years, while also reminding us of how important timely and credible local news and information are to our health and that of our community.
    [Show full text]
  • Drug Delivery Technology Y
    * DDT Nov-Dec 2007 Working 11/9/07 2:29 PM Page 1 November/December 2007 Vol 7 No 10 IN THIS ISSUE Company Profiles 12 Drug Delivery Technologies 58 Excipients, Polymers, Liposomes & Lipids 78 Contract Pharmaceutical & Biological Development Services 83 Machinery & Laboratory Equipment and Software 96 Technology Showcase 102 The science & business of specialty pharma, biotechnology, and drug delivery www.drugdeliverytech.com * DDT Nov-Dec 2007 Working 11/9/07 2:39 PM Page 2 * DDT Nov-Dec 2007 Working 11/9/07 2:40 PM Page 3 * DDT Nov-Dec 2007 Working 11/9/07 2:40 PM Page 4 November/December 2007 Vol 7 No 10 PUBLISHER/PRESIDENT Ralph Vitaro EXECUTIVE EDITORIAL DIRECTOR Dan Marino, MSc [email protected] CREATIVE DIRECTOR Shalamar Q. Eagel CONTROLLER Debbie Carrillo CONTRIBUTING EDITORS Cindy H. Dubin Debra Bingham Jason McKinnie TECHNICAL OPERATIONS Mark Newland EDITORIAL SUPPORT Nicholas D. Vitaro ADMINISTRATIVE SUPPORT Kathleen Kenny Corporate/Editorial Office 219 Changebridge Road, Montville, NJ 07045 Tel: (973)299-1200 Fax: (973) 299-7937 www.drugdeliverytech.com Advertising Sales Offices East & Midwest Victoria Geis - Account Executive Coming in 2008 Cheryl S. Stratos - Account Executive 103 Oronoco Street, Suite 200 Alexandria, VA 22314 Tel: (703) 212-7735 Drug Delivery Weekly & Fax: (703) 548-3733 E-mail: [email protected] Specialty Pharma News E-mail: [email protected] West Coast Warren De Graff Western Regional Manager 818 5th Avenue, Suite 301 San Rafael, CA 94901 Tel: (415) 721-0644 Fax: (415) 721-0665 E-mail: [email protected] 0 The weekly electronic newsletter from the publishers of Drug 1 International o N Delivery Technology and Specialty Pharma will provide over 12,000 Ralph Vitaro 7 219 Changebridge Road l o subscribers with the latest news of business deals, alliances, and V Montville, NJ 07045 Tel: (973) 299-1200 7 technology breakthroughs from the pharmaceutical, specialty 0 Fax: (973) 299-7937 0 2 pharmaceutical, drug delivery, and biotechnology industries.
    [Show full text]
  • DDT Cover/Back April 2006.Qx
    June 2007 Vol 7 No 6 www.drugdeliverytech.com IN THIS ISSUE INTERVIEW WITH EURAND’S CHIEF COMMERCIAL OFFICER MR. JOHN FRAHER The eFlow® Nebulizer 30 Shabtai Bauer, PhD Markus Tservistas, PhD Bioadhesive Microspheres 54 Jayvadan Patel, PhD Transdermal Solutions 68 Gary W. Cleary, PhD FEATURING Imaging CROs 72 Richard Taranto Autoimmune The science & business of specialty pharma, biotechnology, and drug delivery Diseases 80 Douglas Kerr, MD Adam Kaplin, MD JuliaJulia Rashba-Rashba- Shaukat Ali, Richard Step,Step, PhDPhD PhD Sitz, MBA EfEfficientficient PulmonaryPulmonary HMW Povidone Beyond Sticky Partnering With DeliveryDelivery ofof BiologicalBiological PolymerPolymer-Based-Based toto Sophisticated:Sophisticated: NovaQuest 84 MoleculesMolecules asas Films for The Many PROMAXXPROMAXX Fast-Dissolving Dimensions Ms. Cindy H. Dubin MicrMicrospheresospheres Drug Delivery of Adhesives June 2007 Vol 7 No 6 PUBLISHER/PRESIDENT Ralph Vitaro EXECUTIVE EDITORIAL DIRECTOR Dan Marino, MSc [email protected] CREATIVE DIRECTOR Shalamar Q. Eagel CONTROLLER Debbie Carrillo CONTRIBUTING EDITORS Cindy H. Dubin Debra Bingham Jason McKinnie TECHNICAL OPERATIONS Mark Newland EDITORIAL SUPPORT Nicholas D. Vitaro ADMINISTRATIVE SUPPORT Kathleen Kenny Corporate/Editorial Office 219 Changebridge Road, Montville, NJ 07045 Tel: (973)299-1200 Fax: (973) 299-7937 www.drugdeliverytech.com Advertising Sales Offices East & Midwest Victoria Geis - Account Executive Cheryl S. Stratos - Account Executive 103 Oronoco Street, Suite 200 Alexandria, VA 22314 Tel:
    [Show full text]
  • Drug Delivery Technology
    * DDT Nov-Dec 2006 Round 5 11/10/06 7:20 PM Page 2 November/December 2006 Vol 6 No 10 IN THIS ISSUE Corporate Profiles 16 Drug Delivery Technologies 73 Excipients, Polymers, Liposomes & Lipids 90 Contract Pharmaceutical & Biological Development Services 96 Machinery & Laboratory Equipment and Software 109 Technology Spotlight 114 The science & business of specialty pharma, biotechnology, and drug delivery www.drugdeliverytech.com * DDT Nov-Dec 2006 Round 5 11/10/06 7:22 PM Page 3 * DDT Nov-Dec 2006 Round 5 11/10/06 7:22 PM Page 4 * DDT Nov-Dec 2006 Round 5 11/10/06 7:22 PM Page 5 November/December 2006 Vol 6 No 10 PUBLISHER/PRESIDENT Ralph Vitaro EXECUTIVE EDITORIAL DIRECTOR Dan Marino, MSc [email protected] CREATIVE DIRECTOR Shalamar Q. Eagel CONTROLLER Debbie Carrillo CONTRIBUTING EDITORS Cindy H. Dubin Debra Bingham Jason McKinnie TECHNICAL OPERATIONS Mark Newland EDITORIAL SUPPORT Nicholas D. Vitaro ADMINISTRATIVE SUPPORT Kathleen Kenny Corporate/Editorial Office 219 Changebridge Road, Montville, NJ 07045 Tel: (973)299-1200 Fax: (973) 299-7937 www.drugdeliverytech.com Advertising Sales Offices East & Midwest Victoria Geis - Account Executive Cheryl S. Stratos - Account Executive 103 Oronoco Street, Suite 200 Alexandria, VA 22314 Tel: (703) 212-7735 Fax: (703) 548-3733 E-mail: [email protected] E-mail: [email protected] West Coast Warren De Graff Western Regional Manager 818 5th Avenue, Suite 301 San Rafael, CA 94901 Tel: (415) 721-0644 Fax: (415) 721-0665 E-mail: [email protected] International Ralph Vitaro 219 Changebridge Road Vol 6 No 10 Montville, NJ 07045 Tel: (973) 299-1200 Fax: (973) 299-7937 E-mail: [email protected] Mailing List Rental Candy Brecht Tel: (703) 706-0383 Fax: (703) 549-6057 E-mail: [email protected] All editorial submissions are handled with reasonable care, but the publishers assume no responsibility for the safety November/December 2006 of artwork, photographs, or manuscripts.
    [Show full text]
  • Happy-Healthy-Hormones-Latest.Pdf
    HAPPY HEALTHY HORMONES Daved Rosensweet M.D. HOW TO THRIVE IN MENOPAUSE Daved Rosensweet M.D. HOW TO THRIVE IN MENOPAUSE HAPPY HEALTHY HORMONES Daved Rosensweet M.D. HOW TO THRIVE IN MENOPAUSE This book has been written and published to provide information and should not be used as a substitute for the recommendations of your health care professional. Be- cause each person and medical situation are unique, the reader is urged to review this information with a qualified health professional. You should not consider the infor- mation contained in this text to represent the practice of medicine or to replace consultation with a physician or other qualifiedhealth care provider. The Menopause Method, Inc. Sarasota, Florida 941-366-3768 www.menopausemethod.com [email protected] The Menopause Method: A Woman’s Guide to Navigating Menopause, sixth edition, 2017. Copyright © 2001, 2002, 2006, 2007, 2014, 2017 by Daved Rosensweet M.D. All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photo- copying, recording, or otherwise, without the prior written permission of the copyright owner. Sixth Edition 2017 ISBN: 9780999744901 Published in the United States of America Dedication This book is dedicated, first and foremost, to my patients in menopause: for 24 years, woman by woman, moment by moment, molecule by molecule, you have given me what has culminated in these pages. You know who you are, and I do thank you. Writing this dedication has turned out to be a deep and heartfelt experience for me.
    [Show full text]
  • Gives Villa Another Chance
    t Traffic death spots Hurtyrng .to class at new Spreading the word 240 dolls in her INSIDE: in 1965 — Pagfe 2 A DeWitt Hiph —Page 16 A about St. Johns — Page 1 B collection — Page 5 B 'V 110th Year No. 38 People make news as 1966 starts eventfully gives Villa another chance The Villa Dance Hall got a new lease on life last Tuesday *as \'{ ^«5l^ * the city commission permitted them one more chance to stop dis­ orderly activities by dancers on the streets around the hall, "Whatever you try, ithad better work," Commissioner Charles Coletta warned the hall's operators, Mr and Mrs Daniel Salazar'of 705 E. Walker Street. * '' ' * * ROGER^ FEEMAN ARTHUR HALFMANN ADAM BAILEY MRS OLIVER KNIGHT DANIEL BONCHA City police reported good, "clean business and an "es­ HIS ATTORNEY, Lewis, ob­ everything was quiet sentially family type of dance." jected to the revoking of the 11- Feeman Teacher He" agreed to do these things for. , cense. He pointed out that City Boncha, Halfmann, Bailey and the plan apparently Saturday night's (Jan. 8) dance: Atty, Harold Reed's letter advis­ worked well last Sat­ ing Salazar of the show-cause honored 1st crash , —Persons once admitted to the hearing said the trouble was out­ urday night. dance'hall would not be allowed to side the hall. "I don't know of any­ go' "out and come in again, unless thing directed against the dance move up at Federal-Mogul The dance hall area on West hall itself," Lewis said. for service fatality Railroad Street has been the they paid a second admission.
    [Show full text]
  • E-PESO Y5 Annual Report Draft Clean 29
    USAID/E-PESO ACTIVITY 5th Annual Report October 1, 2018 – September 30, 2019 Submission Date: November 29, 2019 Prepared for the United States Agency for International Development by Chemonics International Inc. under Contract No. AID-492-C-15-0001. The author’s views expressed in this publication do not necessarily reflect the views of the United States Agency for International Development or the United States Government. 2 CONTENTS ACRONYMS ................................................................................................................................................................ i EXECUTIVE SUMMARY .......................................................................................................................................... 1 PROGRAM OVERVIEW AND INTRODUCTION ........................................................................................... 3 PROJECT ACHIEVEMENTS .................................................................................................................................... 5 Sub-Purpose 1: Rapid Adoption of e-Payments in Financial Systems .......................................................................... 5 Sub-Purpose 2: Infrastructure for e-Payments Expanded ............................................................................................ 12 Sub-Purpose 3: Enabling Environment for e-Payments Improved .............................................................................. 14 Sub-Purpose 4: Gaps in Broader e-Payment Ecosystem Addressed ........................................................................
    [Show full text]
  • US Mainstream Media Index May 2021.Pdf
    Mainstream Media Top Investors/Donors/Owners Ownership Type Medium Reach # estimated monthly (ranked by audience size) for ranking purposes 1 Wikipedia Google was the biggest funder in 2020 Non Profit Digital Only In July 2020, there were 1,700,000,000 along with Wojcicki Foundation 5B visitors to Wikipedia. (YouTube) Foundation while the largest BBC reports, via donor to its endowment is Arcadia, a Wikipedia, that the site charitable fund of Lisbet Rausing and had on average in 2020, Peter Baldwin. Other major donors 1.7 billion unique visitors include Google.org, Amazon, Musk every month. SimilarWeb Foundation, George Soros, Craig reports over 5B monthly Newmark, Facebook and the late Jim visits for April 2021. Pacha. Wikipedia spends $55M/year on salaries and programs with a total of $112M in expenses in 2020 while all content is user-generated (free). 2 FOX Rupert Murdoch has a controlling Publicly Traded TV/digital site 2.6M in Jan. 2021. 3.6 833,000,000 interest in News Corp. million households – Average weekday prime Rupert Murdoch Executive Chairman, time news audience in News Corp, son Lachlan K. Murdoch, Co- 2020. Website visits in Chairman, News Corp, Executive Dec. 2020: FOX 332M. Chairman & Chief Executive Officer, Fox Source: Adweek and Corporation, Executive Chairman, NOVA Press Gazette. However, Entertainment Group. Fox News is owned unique monthly views by the Fox Corporation, which is owned in are 113M in Dec. 2020. part by the Murdoch Family (39% share). It’s also important to point out that the same person with Fox News ownership, Rupert Murdoch, owns News Corp with the same 39% share, and News Corp owns the New York Post, HarperCollins, and the Wall Street Journal.
    [Show full text]
  • M1 Covered Drug List
    Metallic M1 - List of Covered Drugs (Formulary) Effective Date: 09-01-2021 The Metallic M1 Formulary is used by these plans: Plus HSA Qualified Bronze 5950 Plus HSA Qualified Gold 1500 Plus HSA Qualified Silver 2800 Plus HSA Qualified Silver 3500 Plus HSA Qualified Bronze 6900 What is the list of covered drugs (Formulary)? This document contains a list of generic, brand and specialty drugs covered under your plan. How is the list of covered drugs developed? The drug list is developed with an independent committee of physicians, pharmacists and other healthcare providers called the Pharmacy and Therapeutics Committee. This independent committee reviews and selects drugs for coverage based on each drugs safety, effectiveness and cost. The committee meets at least quarterly to review new drugs to market to determine placement on this list and also reviews updated safety, effectiveness and cost information for existing drugs to ensure the formulary remains up to date with current medical evidence. How do I use the Formulary? Drugs are listed by categories depending on the type of medical conditions that they are used to treat. If you know what your drug is used for, look for the category name in the list that begins below. Then look under the category name for your drug. If you are not sure what category to look under, you can also search for the drug in the Index. The Index provides an alphabetical list of all of the drugs included in this document. Next to the name of the drug in the Index, you will see the page number where you can find coverage information.
    [Show full text]
  • The Philippines Are a Chain of More Than 7,000 Tropical Islands with a Fast Growing Economy, an Educated Population and a Strong Attachment to Democracy
    1 Philippines Media and telecoms landscape guide August 2012 1 2 Index Page Introduction..................................................................................................... 3 Media overview................................................................................................13 Radio overview................................................................................................22 Radio networks..........……………………..........................................................32 List of radio stations by province................……………………………………42 List of internet radio stations........................................................................138 Television overview........................................................................................141 Television networks………………………………………………………………..149 List of TV stations by region..........................................................................155 Print overview..................................................................................................168 Newspapers………………………………………………………………………….174 News agencies.................................................................................................183 Online media…….............................................................................................188 Traditional and informal channels of communication.................................193 Media resources..............................................................................................195 Telecoms overview.........................................................................................209
    [Show full text]
  • Accomplishment Report of the Public Attorney's Office for the Year 2016
    Republiko ng Pilipinos Kogoworon ng Kolorungon Tonggopon ng MonononggolPomboyon (PUBLTC ATTORNEY'S OFFTCE) DOJ Agencies BuiHing, NlARd. mr. East Ave. 1104 Diliman, Quezon City Telephone tlos. 929-90-10i929-9436; FAx Nos. 927$&10/ 926-28-78 ACCOMPLISHMENT REPORT OF THE PUBLIC ATTORNEY'S OFFICE FOR THE YEAR 2016 PREFATORY STATEMENT As protectors of the poor, downtrodden, marginalized, and less privileged in life, the Public Attorney's Office (PAO) has shown wholehearted dedication, enduring perseverance, and unquestionable professionalism in fulfilling its legal mandate of providing free legal services and aid. Guided by the outmost interest to serue the people with respect to their legal needs as mandated by the Constitution, and inspired by the passion and principles which are continually being inculcated upon them, the PAO continues to thrive, adopting to the changes of the present time, as well as taking on the challenges of the ever- growing needs and demands of society. To promote social awareness and reform, the PAO has made efforts to reach a wider audience, aiming to protect the victims of injustices, to educate the less knowledgeable, and to empower those who were weakened. Led by the undersigned, who personally and professionally advocate for the rule of law, truth and social justice to always prevail, the PAO bravely faces the perils and hazards posed by the crucial and the controversial cases it handles, without cowering in fear. Such valiant and dauntless chivalry has become the norm that every PAO employee strives to uphold. With the constant influx of clients, heavy downpour of various cases, and the strict deadlines posed by the prescriptive and reglementary periods imposed by law, the PAO's humble manpower of two thousand, seven hundred and twelve (2,712) employees, stands strong.
    [Show full text]
  • A Review on Transdermal Spray
    Review Article Mathews Journal of Pharmaceutical Science A Review on Transdermal Spray: Formulation Aspect Uttam Kumar Mandal1, Bappaditya Chatterjee1, Fatin Husna Binti Pauzi1 1Department of Pharmaceutical Technology, Kulliyyah of Pharmacy, International Islamic University Malaysia (IIUM), Kuantan, Malaysia. Corresponding Author: Uttam Kumar Mandal, Department of Pharmaceutical Technology, Kulliyyah of Pharmacy, International Islamic University Malaysia (IIUM), Bander Indera Mahkota, Kuantan 25200, Pahang, Malaysia. Tel: +6 0109062750; Email: [email protected] Received Date: 22 Feb 2016 Copyright © 2016 Mandal UK Accepted Date: 24 Mar 2016 Citation: Mandal UK (2016) A Review on Transdermal Spray: Published Date: 30 Mar 2016 Formulation Aspect. M J Pharma 1(1): 006. ABSTRACT Transdermal spray offers numerous advantages over the other conventional transdermal drug delivery forms such as gel, ointment and patches, in terms of its cosmeceutical appearance, ready availability for application, flexibility in dosage design, less occurrence of skin irritation and faster drying rate from the application site due to the use of volatile solvent. However, compared to other transdermal drug delivery dosage forms, transdermal spray has the least and limited num- ber of products approved for marketing. Among the drugs are, Evamist®, an estradiol formulation approved in 2007 by the FDA followed by Axiron® a non-spray solution to treat low testosterone in men and Recuvyra®, a pain reliever solution indicated for dogs. This review article focuses current status on the formulation and evaluation of transdermal spray in the background of the role and effects of its composition specially the selection of drugs, volatile solvents, penetration enhancers and film forming polymer, etc. The limitation of transdermal spray highlighted in this review is the concern of its use, especially, the third party exposure particularly for endocrinology indication.
    [Show full text]